FDA-approved therapies include antibodies such as eculizumab, a complement inhibitor, inebilizumab-cdon, a monoclonal antibody targeting CD19, and satralizumab-mwge, a subcutaneous therapy targeting the IL-6 receptor, all of which are indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive [289]. The gene discussed is AQP4; the disease is neuromyelitis optica.